GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (XPAR:BIM) » Definitions » Price-to-Funds-From-Operations

BioMerieux (XPAR:BIM) Price-to-Funds-From-Operations : (As of Apr. 30, 2024)


View and export this data going back to 2004. Start your Free Trial

What is BioMerieux Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


BioMerieux (XPAR:BIM) Business Description

Traded in Other Exchanges
Address
Marcy l’Etoile, Lyon, FRA, 69280
BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (38% of 2021 sales), microbiology (31%), immunoassays (14%), and industrial applications (about 17%). The Americas account for the largest portion of the firm's revenue (49%), followed by Europe, the Middle East, and Africa (33%), and Asia-Pacific (18%). BioMerieux is headquartered in Marcy-l'Etoile, France.